These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

700 related articles for article (PubMed ID: 18663084)

  • 1. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice.
    Merki E; Graham MJ; Mullick AE; Miller ER; Crooke RM; Pitas RE; Witztum JL; Tsimikas S
    Circulation; 2008 Aug; 118(7):743-53. PubMed ID: 18663084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial.
    Tsimikas S; Witztum JL; Miller ER; Sasiela WJ; Szarek M; Olsson AG; Schwartz GG;
    Circulation; 2004 Sep; 110(11):1406-12. PubMed ID: 15353498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein.
    Tsimikas S; Lau HK; Han KR; Shortal B; Miller ER; Segev A; Curtiss LK; Witztum JL; Strauss BH
    Circulation; 2004 Jun; 109(25):3164-70. PubMed ID: 15184281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
    Fraley AE; Schwartz GG; Olsson AG; Kinlay S; Szarek M; Rifai N; Libby P; Ganz P; Witztum JL; Tsimikas S;
    J Am Coll Cardiol; 2009 Jun; 53(23):2186-96. PubMed ID: 19497447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study.
    Kiechl S; Willeit J; Mayr M; Viehweider B; Oberhollenzer M; Kronenberg F; Wiedermann CJ; Oberthaler S; Xu Q; Witztum JL; Tsimikas S
    Arterioscler Thromb Vasc Biol; 2007 Aug; 27(8):1788-95. PubMed ID: 17541022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin.
    Rodenburg J; Vissers MN; Wiegman A; Miller ER; Ridker PM; Witztum JL; Kastelein JJ; Tsimikas S
    J Am Coll Cardiol; 2006 May; 47(9):1803-10. PubMed ID: 16682304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study.
    Tsimikas S; Kiechl S; Willeit J; Mayr M; Miller ER; Kronenberg F; Xu Q; Bergmark C; Weger S; Oberhollenzer F; Witztum JL
    J Am Coll Cardiol; 2006 Jun; 47(11):2219-28. PubMed ID: 16750687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity.
    Tsimikas S; Witztum JL
    Curr Opin Lipidol; 2008 Aug; 19(4):369-77. PubMed ID: 18607184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidized low-density lipoprotein biomarkers in patients with end-stage renal failure: acute effects of hemodialysis.
    Bossola M; Tazza L; Merki E; Giungi S; Luciani G; Miller ER; Lin EB; Tortorelli A; Tsimikas S
    Blood Purif; 2007; 25(5-6):457-65. PubMed ID: 18075247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice.
    Merki E; Graham M; Taleb A; Leibundgut G; Yang X; Miller ER; Fu W; Mullick AE; Lee R; Willeit P; Crooke RM; Witztum JL; Tsimikas S
    J Am Coll Cardiol; 2011 Apr; 57(15):1611-21. PubMed ID: 21474042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease.
    Tsimikas S; Brilakis ES; Miller ER; McConnell JP; Lennon RJ; Kornman KS; Witztum JL; Berger PB
    N Engl J Med; 2005 Jul; 353(1):46-57. PubMed ID: 16000355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease.
    Tsimikas S; Tsironis LD; Tselepis AD
    Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2094-9. PubMed ID: 17626905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heritability of Biomarkers of Oxidized Lipoproteins: Twin Pair Study.
    Rao F; Schork AJ; Maihofer AX; Nievergelt CM; Marcovina SM; Miller ER; Witztum JL; O'Connor DT; Tsimikas S
    Arterioscler Thromb Vasc Biol; 2015 Jul; 35(7):1704-11. PubMed ID: 25953646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An apolipoprotein(a) peptide delays chylomicron remnant clearance and increases plasma remnant lipoproteins and atherosclerosis in vivo.
    Devlin CM; Lee SJ; Kuriakose G; Spencer C; Becker L; Grosskopf I; Ko C; Huang LS; Koschinsky ML; Cooper AD; Tabas I
    Arterioscler Thromb Vasc Biol; 2005 Aug; 25(8):1704-10. PubMed ID: 15905467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The I4399M variant of apolipoprotein(a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles.
    Arai K; Luke MM; Koschinsky ML; Miller ER; Pullinger CR; Witztum JL; Kane JP; Tsimikas S
    Atherosclerosis; 2010 Apr; 209(2):498-503. PubMed ID: 19880117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipoprotein(A) with An Intact Lysine Binding Site Protects the Retina From an Age-Related Macular Degeneration Phenotype in Mice (An American Ophthalmological Society Thesis).
    Handa JT; Tagami M; Ebrahimi K; Leibundgut G; Janiak A; Witztum JL; Tsimikas S
    Trans Am Ophthalmol Soc; 2015; 113():T5. PubMed ID: 26538774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a).
    Yeang C; Hung MY; Byun YS; Clopton P; Yang X; Witztum JL; Tsimikas S
    J Clin Lipidol; 2016; 10(3):594-603. PubMed ID: 27206947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OxPL/apoB, lipoprotein(a) and OxLDL biomarkers and cardiovascular disease in chronic hemodialysis patients.
    Bossola M; Tazza L; Luciani G; Tortorelli A; Tsimikas S
    J Nephrol; 2011; 24(5):581-8. PubMed ID: 21404224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mipomersen, an antisense apolipoprotein B synthesis inhibitor.
    Bell DA; Hooper AJ; Burnett JR
    Expert Opin Investig Drugs; 2011 Feb; 20(2):265-72. PubMed ID: 21210756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study.
    Tsimikas S; Clopton P; Brilakis ES; Marcovina SM; Khera A; Miller ER; de Lemos JA; Witztum JL
    Circulation; 2009 Apr; 119(13):1711-9. PubMed ID: 19307470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.